 | Up a level |
Schandelmaier, S; Conen, K; von Elm, E; You, J J; Blümle, A; Tomonaga, Y; Saccilotto, R; Amstutz, A; Bengough, T; Meerpohl, J J; Stegert, M; Olu, K K; Tikkinen, K A O; Neumann, I; Carrasco-Labra, A; Faulhaber, M; Mulla, S M; Mertz, D; Akl, E A; Sun, X; ... (2015). Planning and reporting of quality-of-life outcomes in cancer trials. Annals of oncology, 26(9), pp. 1966-1973. Oxford University Press 10.1093/annonc/mdv283
Pittet, V; Juillerat, P; Michetti, P; Vader, J-P; Burnand, B; Rogler, G; Beglinger, C; Seibold, F; Mottet, C; Felley, C; Gonvers, J-J; Froehlich, F; Swiss IBD Cohort Study Group, The (2010). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary pharmacology & therapeutics, 32(8), pp. 1007-16. Oxford: Wiley-Blackwell 10.1111/j.1365-2036.2010.04434.x
Pittet, V; Juillerat, P; Mottet, C; Felley, C; Ballabeni, P; Burnand, B; Michetti, P; Vader, JP; and, the Swiss IBD Cohort Study Group (2009). Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). International journal of epidemiology, 38(4), pp. 922-31. Oxford: Oxford University Press 10.1093/ije/dyn180
Juillerat, Pascal; Sokol, H; Froehlich, F; Burnand, B; Yajnik, V; Beaugerie, L; Macpherson, Andrew; Cosnes, J; Korzenik, JR (2014). Facteurs associés à une réponse à l’infliximab prolongée au-delà de 5 ans : une étude de cohorte multi-centrique internationale (Unpublished). In: Journées Francophones d’Hépatologie-gastroentérologie et d’Oncologie Digestives. Paris.
